Cellectis grants additional rights to Servier
to develop and commercialize all next generation gene-edited
allogeneic CAR T-cell products targeting CD19, including
ALLO-501A
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS;
Nasdaq: CLLS), a biopharmaceutical company focused on developing
immunotherapies based on gene-edited allogeneic CAR T-cells
(UCART), and Servier, an international pharmaceutical company,
today announced the execution of a binding term sheet to enter into
an amendment to the agreement initially signed between the two
companies in 2014.
Under the term sheet, Cellectis shall grant to Servier, through
an amendment to the agreement, an expanded exclusive worldwide
license to develop and commercialize all next generation
gene-edited allogeneic CAR T-cell products targeting CD19,
including rights to ALLO-501A, an anti-CD19 candidate in which the
rituximab recognition domains have been removed, either directly or
through its US sublicensee Allogene Therapeutics.
In this amendment, financial terms will be improved to include
an additional USD 27.6 million (EUR 25 million) upfront payment, as
well as up to USD 410 million (EUR 370 million) in clinical and
commercial milestones. The royalty rate will be increased from
tiered high single-digit royalties to flat low double-digit
royalties based on net sales of products.
In addition, pursuant to the amendment, Cellectis shall regain
exclusive control over the five undisclosed allogeneic CAR T-cell
targets previously covered by the initial agreement.
The amendment will be effective upon its execution.
“This amendment to our license agreement with Servier provides
to Cellectis an attractive economic upside to product candidates
targeting CD19 and enriches our proprietary portfolio of targets,”
said Dr. André Choulika, Chairman and CEO, Cellectis. “We are
committed to positioning Servier and Allogene for streamlined
success, so the CD19-directed products have the potential to reach
patients faster, while also providing Cellectis the means to expand
our proprietary product pipeline.”
About UCART19/ALLO-501 and ALLO-501A
UCART19/ALLO-501 and ALLO-501A are two anti-CD19 allogeneic
CAR-T product candidates being jointly developed under a clinical
development collaboration between Servier and Allogene Therapeutics
based on an exclusive license granted by Cellectis to Servier.
Such products utilize Cellectis’ technologies, including TALEN®
gene editing technology pioneered and controlled by Cellectis.
Servier grants to Allogene exclusive rights to UCART19 in the US
while Servier retains exclusive rights for all other countries.
About Cellectis
Cellectis is developing the first of its kind allogeneic
approach for CAR-T immunotherapies in oncology, pioneering the
concept of off-the-shelf and ready-to-use gene-edited CAR T-cells
to treat cancer patients. As a clinical-stage biopharmaceutical
company with over 20 years of expertise in gene editing, Cellectis
is developing life-changing product candidates utilizing TALEN®,
its gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated
to its goal of providing life-saving UCART product candidates to
address unmet needs for multiple cancers including acute myeloid
leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL),
multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).
Cellectis headquarters are in Paris, France, with additional
locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS). For more information, visit
www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and
YouTube.
TALEN® is a registered trademark owned by Cellectis.
About Servier
Servier is an international pharmaceutical company governed by a
non-profit foundation, with its headquarters in France (Suresnes).
With a strong international presence in 149 countries and a
turnover of 4.2 billion euros in 2018, Servier employs 22 000
people worldwide. Entirely independent, the Group reinvests 25% of
its turnover (excluding generics) in research and development and
uses all its profits for development. Corporate growth is driven by
Servier’s constant search for innovation in five areas of
excellence: cardiovascular, immune-inflammatory and
neurodegenerative diseases, cancer and diabetes, as well as by its
activities in high-quality generic drugs. Servier also offers
eHealth solutions beyond drug development.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risk
factors that may affect company business and financial performance
is included in Cellectis’ Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2018 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200218006051/en/
Media: Jennifer Moore, VP of Communications,
917-580-1088, media@cellectis.com Caitlin Kasunich, KCSA Strategic
Communications, 212-896-1241, ckasunich@kcsa.com
IR: Simon Harnest, VP of Corporate Strategy and Finance,
646-385-9008, simon.harnest@cellectis.com
Servier Group Press: Sonia Marques : presse@servier.com – +33
(0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13 Jean-Clément Vergeau :
presse@servier.com – +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75
96
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Jul 2023 to Jul 2024